Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -453.6%. (2005–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $10M | $4M | $16M | $82M | $122M | $69M | $66M | $295M | $254M | $338M |
| Enterprise Value | $10M | $11M | $4M | $12M | $75M | $111M | $66M | $63M | $292M | $244M | $337M |
| P/E Ratio → | -0.58 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.90 | 1.05 | 0.41 | 1.09 | 8.05 | 12.31 | 10.49 | 5.27 | 16.18 | 21.32 | 77.14 |
| P/B Ratio | — | — | 1.29 | 1.49 | 8.08 | 9.92 | 71.17 | 13.30 | 113.72 | 35.72 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.17 | 0.37 | 0.86 | 7.37 | 11.15 | 10.06 | 5.01 | 16.01 | 20.52 | 76.97 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.3% | 66.3% | 58.2% | 54.0% | 63.8% | 60.0% | 73.7% | 88.0% | 84.7% | 79.3% | 71.2% |
| Operating Margin | -59.7% | -59.7% | -39.2% | -100.1% | -86.8% | -64.7% | -142.4% | -62.9% | -40.1% | -92.3% | -479.7% |
| Net Profit Margin | -73.8% | -73.8% | -92.2% | -73.6% | -57.1% | -111.1% | -146.4% | -52.3% | -40.6% | -110.5% | -433.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -453.6% | -453.6% | -139.0% | -102.4% | -51.8% | -166.1% | -325.9% | -173.4% | -152.7% | -1313.1% | — |
| ROA | -116.0% | -116.0% | -75.8% | -52.5% | -29.7% | -83.4% | -93.9% | -67.3% | -58.2% | -128.6% | -300.8% |
| ROIC | -217.0% | -217.0% | -60.6% | -206.9% | -325.3% | -554.6% | — | -1012.6% | — | — | — |
| ROCE | -218.9% | -218.9% | -48.6% | -88.2% | -53.8% | -71.6% | -170.2% | -148.3% | -90.5% | -191.0% | -906.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.83 | 0.19 | 0.05 | 0.04 | 4.16 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.12 | -0.31 | -0.68 | -0.93 | -2.97 | -0.64 | -1.23 | -1.34 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.46 | -6.46 | -2.42 | — | — | — | -8.93 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.68 | 0.68 | 1.67 | 2.66 | 3.83 | 5.03 | 1.65 | 2.24 | 1.81 | 3.35 | 0.98 |
| Quick Ratio | 0.41 | 0.41 | 1.00 | 1.85 | 2.89 | 4.81 | 1.56 | 2.16 | 1.71 | 3.15 | 0.69 |
| Cash Ratio | 0.15 | 0.15 | 0.73 | 1.26 | 2.18 | 4.22 | 1.22 | 0.83 | 0.64 | 2.20 | 0.51 |
| Asset Turnover | — | 2.86 | 1.16 | 0.88 | 0.43 | 0.65 | 0.59 | 1.34 | 1.81 | 0.77 | 0.86 |
| Inventory Turnover | 4.31 | 4.31 | 1.52 | 1.93 | 1.15 | 6.53 | 3.53 | 5.37 | 5.52 | 2.82 | 0.94 |
| Days Sales Outstanding | — | 14.52 | 26.50 | 51.09 | 60.31 | 40.64 | 58.96 | 101.93 | 74.38 | 70.10 | 44.66 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $3M | $120001 | $46000 | $35629 | $28633 | $17666 | $13925 | $12509 | $12549 | $27314 |
Existential liquidity crisis
According to recent market data, NovaBay trades at a price-to-sales ratio of 0.90, a multiple that suggests investors are pricing the company closer to its liquidation value rather than as a viable, growing enterprise capable of generating future cash flows from its core Avenova product line.
The lack of a meaningful P/E or EV/EBITDA multiple highlights the market's skepticism regarding the company's ability to reach profitability. Investors should interpret this low valuation as a reflection of the significant dilution risk inherent in a business model that requires constant capital injections to survive.
As reported in historical financial statements, NovaBay's ROIC has consistently remained in negative territory, reaching -7.9% in 2025Q3, which demonstrates that the company is currently destroying shareholder value rather than compounding it through its operational activities or strategic acquisitions like DERMAdoctor.
The persistent negative returns on capital suggest that the firm's investments in marketing and product development are not yielding sufficient incremental returns to cover the cost of capital. This trend warrants further investigation into whether the current business model can ever achieve the efficiency required to generate positive economic profit.
Based on the company's reported figures, the cash conversion cycle has exhibited extreme volatility, with DSO reaching 258 days in 2025Q3, indicating that NovaBay is struggling to collect on its receivables effectively compared to its historical performance and broader industry standards for specialty pharmaceutical firms.
The extended collection period suggests that the company may be facing challenges with its retail distribution partners or is forced to offer lenient terms to maintain sales volume. Such inefficiencies in working capital management exacerbate the company's already precarious cash position and limit its operational flexibility.
As indicated by recent quarterly filings, the current ratio of 2.00 masks a severe underlying cash shortage, as the company's liquid assets are insufficient to cover the ongoing operating losses and debt obligations without relying on further dilutive financing or external capital support.
While the current ratio appears superficially adequate, the reliance on inventory and receivables to meet short-term obligations is risky given the company's negative cash flow. Investors should monitor the cash burn rate closely, as the current liquidity profile leaves almost no margin for error in the event of a market downturn.
The price-to-sales ratio is frequently misapplied to NovaBay, as it obscures the company's structural unprofitability and the high likelihood of equity dilution, which effectively transfers value from existing shareholders to new capital providers in order to sustain the firm's ongoing operations.
For a company in this stage of distress, a focus on revenue multiples ignores the reality that every dollar of sales is currently being generated at a loss. A more appropriate metric for this business model would be the cash burn rate relative to the remaining cash runway, which provides a clearer picture of the company's survival prospects.
Includes 30+ ratios · 20 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBY stock.
NovaBay Pharmaceuticals, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
NovaBay Pharmaceuticals, Inc.'s return on equity (ROE) is -453.6%. The historical average is -143.3%.
Based on historical data, NovaBay Pharmaceuticals, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
NovaBay Pharmaceuticals, Inc. has 66.3% gross margin and -59.7% operating margin.